The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33(6):1224–9.Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of ...
The first generation ofsulfonylureasare rarely ever used these days and include drugs like tolbutamide, chlorpropamide and tolazamide. The second generationsulfonylureasinclude glimepiride, glyburide (glibenclamide), glipizide, and gliclazide and are widely used as these are much safer and more potent ...
(EHR) system to identify 23 915 patients with type 2 diabetes who initiated monotherapy with metformin (N = 12774), glipizide (N = 4325), glyburide (N = 4279) or glimepiride (N = 2537), 18 years of age, with and without a history of CAD, and not on insulin or a non-insulin ...
Increased risk of overall mortality in patients with type 2 diabetes receiving glipizide, Glyburide, and Glimepiride vs. Metformin. A Retrospective AnalysisK.M., PantaloneM.W., KattanC., YuB.J., WellsS., ArrigainA., JainA., Atreja